Analysis: Industry observers differ over future of big pharma stocks

10/12/2004 | NYTimes.com

Drug stocks have underperformed the broad market since February, and while financial analysts agree large pharmaceutical company stock prices are low, a looming election, patent expirations and hard bargaining by HMOs, among other factors, have many analysts disagreeing over what the future holds. Some analysts fear more regulatory pressure on drug companies with a change in presidents, while others see a Democratic president being held in check by a GOP Congress. Some are investing in other areas of health care, such as medical instruments and biotechnology.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Chief Executive Officer
UCare Minnesota
Minneapolis, MN
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC